• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

联合对接和机器学习确定β2 肾上腺素能受体配体药理活性的关键分子决定因素。

Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on β2 adrenoceptor.

机构信息

Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK.

Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK.

出版信息

Pharmacol Res Perspect. 2022 Oct;10(5):e00994. doi: 10.1002/prp2.994.

DOI:10.1002/prp2.994
PMID:36029004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9418666/
Abstract

G protein-coupled receptors (GPCRs) are valuable therapeutic targets for many diseases. A central question of GPCR drug discovery is to understand what determines the agonism or antagonism of ligands that bind them. Ligands exert their action via the interactions in the ligand binding pocket. We hypothesized that there is a common set of receptor interactions made by ligands of diverse structures that mediate their action and that among a large dataset of different ligands, the functionally important interactions will be over-represented. We computationally docked ~2700 known β2AR ligands to multiple β2AR structures, generating ca 75 000 docking poses and predicted all atomic interactions between the receptor and the ligand. We used machine learning (ML) techniques to identify specific interactions that correlate with the agonist or antagonist activity of these ligands. We demonstrate with the application of ML methods that it is possible to identify the key interactions associated with agonism or antagonism of ligands. The most representative interactions for agonist ligands involve K97 , F194 , S203 , S204 , S207 , H296 , and K305 . Meanwhile, the antagonist ligands made interactions with W286 and Y316 , both residues considered to be important in GPCR activation. The interpretation of ML analysis in human understandable form allowed us to construct an exquisitely detailed structure-activity relationship that identifies small changes to the ligands that invert their pharmacological activity and thus helps to guide the drug discovery process. This approach can be readily applied to any drug target.

摘要

G 蛋白偶联受体(GPCRs)是许多疾病的有价值的治疗靶点。GPCR 药物发现的一个核心问题是了解哪些因素决定了结合它们的配体的激动剂或拮抗剂性质。配体通过结合口袋中的相互作用发挥作用。我们假设存在一组由不同结构的配体介导其作用的共同受体相互作用,并且在大量不同配体的数据集,功能重要的相互作用将被过度代表。我们通过计算将大约 2700 种已知的β2AR 配体对接至多个β2AR 结构,生成大约 75000 个对接构象,并预测了受体与配体之间的所有原子相互作用。我们使用机器学习(ML)技术来识别与这些配体的激动剂或拮抗剂活性相关的特定相互作用。我们通过 ML 方法的应用证明,识别与配体激动剂或拮抗剂性质相关的关键相互作用是可能的。激动剂配体的最具代表性的相互作用涉及 K97、F194、S203、S204、S207、H296 和 K305。同时,拮抗剂配体与 W286 和 Y316 发生相互作用,这两个残基被认为在 GPCR 激活中很重要。以人类可理解的形式解释 ML 分析使我们能够构建一个非常详细的结构-活性关系,该关系识别出改变配体的微小变化,从而反转其药理活性,从而有助于指导药物发现过程。这种方法可以很容易地应用于任何药物靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/7c1390789175/PRP2-10-e00994-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/8a4e3d380eee/PRP2-10-e00994-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/cbaeeba44254/PRP2-10-e00994-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/dd668667d474/PRP2-10-e00994-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/d9c8d7b42ca2/PRP2-10-e00994-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/7c1390789175/PRP2-10-e00994-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/8a4e3d380eee/PRP2-10-e00994-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/cbaeeba44254/PRP2-10-e00994-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/dd668667d474/PRP2-10-e00994-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/d9c8d7b42ca2/PRP2-10-e00994-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce87/9418666/7c1390789175/PRP2-10-e00994-g001.jpg

相似文献

1
Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on β2 adrenoceptor.联合对接和机器学习确定β2 肾上腺素能受体配体药理活性的关键分子决定因素。
Pharmacol Res Perspect. 2022 Oct;10(5):e00994. doi: 10.1002/prp2.994.
2
Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.基于结构的 G 蛋白偶联受体配体功能预测:β-肾上腺素能受体案例研究。
J Chem Inf Model. 2015 May 26;55(5):1045-61. doi: 10.1021/acs.jcim.5b00066. Epub 2015 May 1.
3
A Machine Learning Approach for the Discovery of Ligand-Specific Functional Mechanisms of GPCRs.一种用于发现 GPCR 配体特异性功能机制的机器学习方法。
Molecules. 2019 Jun 2;24(11):2097. doi: 10.3390/molecules24112097.
4
Molecular interactions between fenoterol stereoisomers and derivatives and the β₂-adrenergic receptor binding site studied by docking and molecular dynamics simulations.通过对接和分子动力学模拟研究芬特罗对映异构体和衍生物与 β₂-肾上腺素能受体结合位点的分子相互作用。
J Mol Model. 2013 Nov;19(11):4919-30. doi: 10.1007/s00894-013-1981-y. Epub 2013 Sep 17.
5
Automated discovery of GPCR bioactive ligands.GPCR 生物活性配体的自动发现。
Curr Opin Struct Biol. 2019 Apr;55:17-24. doi: 10.1016/j.sbi.2019.02.011. Epub 2019 Mar 23.
6
Analysis of L-DOPA and droxidopa binding to human β-adrenergic receptor.分析 L-DOPA 和 droxidopa 与人β-肾上腺素能受体的结合。
Biophys J. 2021 Dec 21;120(24):5631-5643. doi: 10.1016/j.bpj.2021.11.007. Epub 2021 Nov 10.
7
Ligand and Structure Based Models for the Identification of Beta 2 Adrenergic Receptor Antagonists.基于配体和结构的β2肾上腺素能受体拮抗剂识别模型
Curr Comput Aided Drug Des. 2015;11(3):222-36. doi: 10.2174/1573409911666150812130420.
8
Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening?晶体结构是否排除了基于结构的虚拟筛选中 G 蛋白偶联受体理论模型的需要?
Proteins. 2012 Jun;80(6):1503-21. doi: 10.1002/prot.24035. Epub 2012 Mar 13.
9
Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators.识别β₂肾上腺素能受体的构象变化,以实现对配体/受体相互作用的准确预测并筛选G蛋白偶联受体调节剂。
J Comput Aided Mol Des. 2009 May;23(5):273-88. doi: 10.1007/s10822-008-9257-9. Epub 2009 Jan 16.
10
Trends in application of advancing computational approaches in GPCR ligand discovery.推进计算方法在 GPCR 配体发现中的应用趋势。
Exp Biol Med (Maywood). 2021 May;246(9):1011-1024. doi: 10.1177/1535370221993422. Epub 2021 Feb 27.

引用本文的文献

1
Ligand-Induced Biased Activation of GPCRs: Recent Advances and New Directions from In Silico Approaches.G蛋白偶联受体的配体诱导偏向性激活:计算机模拟方法的最新进展与新方向
Molecules. 2025 Feb 25;30(5):1047. doi: 10.3390/molecules30051047.
2
A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression.一种由嵌合膜包被DNA纳米笼包裹的MORC2选择性抑制剂靶向缓解三阴性乳腺癌进展。
Mater Today Bio. 2025 Jan 19;31:101497. doi: 10.1016/j.mtbio.2025.101497. eCollection 2025 Apr.
3
AiGPro: a multi-tasks model for profiling of GPCRs for agonist and antagonist.

本文引用的文献

1
The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials.2022 年 IUPHAR/BPS 药理学指南:为 COVID-19、疟疾和抗菌药物药物治疗学。
Nucleic Acids Res. 2022 Jan 7;50(D1):D1282-D1294. doi: 10.1093/nar/gkab1010.
2
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.《2021/22药理学简明指南:G蛋白偶联受体》
Br J Pharmacol. 2021 Oct;178 Suppl 1:S27-S156. doi: 10.1111/bph.15538.
3
Structural insights into differences in G protein activation by family A and family B GPCRs.
AiGPro:一种用于G蛋白偶联受体激动剂和拮抗剂分析的多任务模型。
J Cheminform. 2025 Jan 29;17(1):12. doi: 10.1186/s13321-024-00945-7.
4
Mechanisms and technologies in cancer epigenetics.癌症表观遗传学的机制与技术
Front Oncol. 2025 Jan 7;14:1513654. doi: 10.3389/fonc.2024.1513654. eCollection 2024.
5
Leveraging Artificial Intelligence in GPCR Activation Studies: Computational Prediction Methods as Key Drivers of Knowledge.利用人工智能进行 G 蛋白偶联受体激活研究:计算预测方法作为知识的关键驱动力。
Methods Mol Biol. 2025;2870:183-220. doi: 10.1007/978-1-0716-4213-9_10.
6
Fingerprinting Interactions between Proteins and Ligands for Facilitating Machine Learning in Drug Discovery.为促进药物发现中的机器学习而进行蛋白质与配体相互作用的指纹图谱绘制。
Biomolecules. 2024 Jan 5;14(1):72. doi: 10.3390/biom14010072.
7
AI-based identification of therapeutic agents targeting GPCRs: introducing ligand type classifiers and systems biology.基于人工智能的靶向G蛋白偶联受体的治疗药物鉴定:引入配体类型分类器和系统生物学
Chem Sci. 2023 Jul 24;14(32):8651-8661. doi: 10.1039/d3sc02352d. eCollection 2023 Aug 16.
8
Activity Map and Transition Pathways of G Protein-Coupled Receptor Revealed by Machine Learning.机器学习揭示的 G 蛋白偶联受体的活动图谱和跃迁途径。
J Chem Inf Model. 2023 Apr 24;63(8):2296-2304. doi: 10.1021/acs.jcim.3c00032. Epub 2023 Apr 10.
对A类和B类G蛋白偶联受体激活G蛋白差异的结构见解。
Science. 2020 Jul 31;369(6503). doi: 10.1126/science.aba3373.
4
GPCRmd uncovers the dynamics of the 3D-GPCRome.GPCRmd 揭示了 3D-GPCRome 的动态变化。
Nat Methods. 2020 Aug;17(8):777-787. doi: 10.1038/s41592-020-0884-y. Epub 2020 Jul 13.
5
From Local Explanations to Global Understanding with Explainable AI for Trees.利用可解释人工智能实现从局部解释到树木的全局理解
Nat Mach Intell. 2020 Jan;2(1):56-67. doi: 10.1038/s42256-019-0138-9. Epub 2020 Jan 17.
6
The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY.2020 年国际药理学联合会/英国药理学学会药物学指南:扩充免疫药理学内容并推出国际药理学联合会/MMV 疟疾药物学指南。
Nucleic Acids Res. 2020 Jan 8;48(D1):D1006-D1021. doi: 10.1093/nar/gkz951.
7
Pharmacological treatment and current controversies in COPD.慢性阻塞性肺疾病(COPD)的药物治疗及当前争议
F1000Res. 2019 Aug 29;8. doi: 10.12688/f1000research.19811.1. eCollection 2019.
8
Ultra-LABAs for the treatment of asthma.超长效β2 激动剂治疗哮喘。
Respir Med. 2019 Sep;156:47-52. doi: 10.1016/j.rmed.2019.08.005. Epub 2019 Aug 12.
9
ChEMBL: towards direct deposition of bioassay data.ChEMBL:致力于直接生成生物测定数据。
Nucleic Acids Res. 2019 Jan 8;47(D1):D930-D940. doi: 10.1093/nar/gky1075.
10
A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening.一种源自每个原子分数贡献的新型相互作用指纹:对接虚拟筛选中相互作用指纹性能的详尽评估。
J Cheminform. 2018 Mar 16;10(1):15. doi: 10.1186/s13321-018-0264-0.